New to peptides? Start with the foundations ->
Why people use TB-500 for hamstring injury
Pulled your hamstring (sprinting / hockey / soccer). TB-500? The short answer: yes, this is one of the more-discussed uses for TB-500 - but the evidence quality and the right protocol depend on what you're actually trying to fix.
This page covers what's known, what's not, and what the editorial take is for normal humans considering TB-500 for hamstring injury.
What the evidence says
Evidence tier: Moderate anecdotal. Strong real-world anecdotal track record; mechanism extrapolates from related research.
- Athletes' favored peptide for muscle-tear recovery, particularly high-velocity injuries.
- Pairs well with eccentric rehab protocols.
- No RCT data; mechanism extrapolates from animal soft-tissue work.
Protocol notes
2mg twice weekly for 4 weeks. Resume sport gradually with PT clearance.
Always with a sports-medicine doctor, telehealth provider, or specialist sign-off. Self-experimenting on injection schedules without clinical input is the most common way people waste money and get hurt.
What to skip
- Vendors without a Certificate of Analysis (COA). Random gym-bro vendors with no third-party testing. The peptide market has a quality-control problem; the answer is COA per peptide, every time.
- Pre-mixed blends from non-pharmacy sources. Compounding pharmacies that produce pre-mixed combinations with COAs are fine. Random vendor "stack vials" are not.
- Massively over-dosed protocols. More is rarely better with peptides. Receptor saturation is real. Stick to evidence-based dosing.
Where to go next
- Full TB-500 directory entry - status, sourcing, studies, what to skip
- What are peptides - if you skipped the foundation
- How peptides actually work - mechanism in plain English
- The Tier List - which ones to take seriously
- Subscribe to the dispatch
Subscribe to the dispatch
The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read. Broken down for normal humans.
Last reviewed · 2026-05-07 · Page generated by Protocol One matrix engine